Law360 (April 9, 2021, 5:21 PM EDT) -- While the U.S. Food and Drug Administration has not initiated widespread enforcement against makers and sellers of CBD products, it continues to bring targeted enforcement where claims or other factors raise particular issues ripe for enforcement.
Most recently, the agency issued two warning letters to makers of topical CBD products labeled as over-the-counter, or OTC, drugs.
Both warning letters followed facility inspections where the FDA identified significant concerns related to current good manufacturing practice requirements, signaling that these concerns may have been the primary impetus for enforcement. But there were also other issues with important takeaways for manufacturers and sellers of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!